Leibovitch Emily C, Jacobson Steven
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Institute for Biomedical Sciences, School of Medicine and Health Sciences of The George Washington University, Washington, DC, USA.
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Curr Opin Virol. 2014 Dec;9:127-33. doi: 10.1016/j.coviro.2014.09.016. Epub 2014 Oct 17.
Following reports of elevated antiviral antibodies in MS patient sera and viral DNA detection in MS plaques nearly two decades ago, the neurovirology community has actively explored how herpesviruses such as HHV-6 might be involved in MS disease pathogenesis. Though findings across the field are non-uniform, an emerging consensus of viral correlates with disease course and evidence of HHV-6-specific immune responses in the CNS provide compelling evidence for a role, direct or indirect, of this virus in MS. Ultimately, the only way to demonstrate the involvement, or lack thereof, of HHV-6 or other herpesviruses in this disease is through a controlled clinical trial of an efficacious antiviral drug.
大约二十年前,有报道称多发性硬化症(MS)患者血清中的抗病毒抗体水平升高,且在MS斑块中检测到病毒DNA,此后神经病毒学界一直在积极探索诸如人类疱疹病毒6型(HHV-6)等疱疹病毒可能如何参与MS疾病的发病机制。尽管该领域的研究结果并不一致,但关于病毒与病程的相关性以及中枢神经系统中HHV-6特异性免疫反应的证据不断涌现,有力地证明了这种病毒在MS中直接或间接发挥的作用。最终,要证明HHV-6或其他疱疹病毒是否参与这种疾病,唯一的方法是通过对一种有效的抗病毒药物进行对照临床试验。